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Summary
Inhibitor development is a major complication of treatment with factor
VIII concentrates in nonsevere haemophilia A. It has been suggested that
plasma-derived factor VIII (FVIII) concentrates elicit fewer inhibitors than
recombinant FVIII concentrates, but studies in severe haemophilia A
patients have shown conflicting results. We designed a case–control study
to investigate the clinical and genetic risk factors for inhibitor development
in nonsevere haemophilia A patients. We investigated whether the type of
FVIII concentrate was associated with inhibitor development in nonsevere
haemophilia A patients. This nested case–control study includes 75 inhibi-
tor patients and 223 controls, from a source population of the INSIGHT
study, including all nonsevere haemophilia A patients (FVIII:C 2–40%) that
were treated with FVIII concentrates in 33 European and one Australian
centre. Cases and controls were matched for date of birth and cumulative
number of exposure days (CED) to FVIII concentrate. A conditional logis-
tic regression model was used to calculate unadjusted and adjusted odds
ratios. No increased risk for inhibitor development was found for any type
of FVIII concentrate; either when comparing recombinant FVIII concen-
trates to plasma-derived FVIII concentrates (adjusted odds ratio 096, 95%
confidence interval (CI) 036–252) or for specific types of FVIII concen-
trates.
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Haemophilia A (HA) is a X-linked inherited bleeding disor-
der resulting from a deficiency of clotting factor VIII. The
disease is categorised based on the residual factor VIII activ-
ity level. In general, patients with mild or moderate (nonsev-
ere) disease only experience bleeding complications after
trauma or surgery. Factor VIII (FVIII) concentrates are
administered to prevent or treat bleeding, but patients can
develop anti-FVIII antibodies (inhibitors), which is a major
complication of this treatment. These antibodies render the
replacement therapy with FVIII concentrates ineffective and
result in increased morbidity and mortality (Hay et al., 1998;
Darby et al., 2004; Eckhardt et al., 2015).
We need to identify risk factors for the development of
inhibitors in HA patients to enable the identification of high
risk patients, and to design patient-tailored treatment pre-
venting the development of inhibitors.
Genetic risk factors for inhibitor development in HA
patients that have been identified and studied are the F8 geno-
type and polymorphisms in several immunoregulatory genes
(Astermark et al., 2006a, 2006b, 2007,b, 2007; Gouw & Van
Den Berg, 2009). Several treatment-related risk factors for
inhibitors have been studied, mostly in severe HA patients,
such as age and treatment intensity at first exposure, the
reason for treatment (e.g. surgery), and the dose of FVIII.
Additionally, the type of FVIII concentrate used for treat-
ment is one of the most debated risk factors. After the intro-
duction of recombinant FVIII concentrates (recFVIII), it has
been suggested that plasma-derived factor VIII concentrates
(pdFVIII) elicit fewer inhibitors than recombinant FVIII con-
centrates. It is recognised that inhibitor screening practice
intensified after introduction of recFVIII in the early expo-
sure days (EDs) of severe HA, leading to greater detection of
any anti-FVIII antibody activity.
One of the hypotheses for plasma-derived FVIII concen-
trates being less immunogenic is based on the presence of
varying amounts of von Willebrand factor in pdFVIII con-
centrates, depending on the specific brand and manufactur-
ing process. In vitro studies have shown that the von
Willebrand factor (VWF) which is present in pdFVIII poten-
tially masks inhibitor epitopes on the FVIII protein (Delignat
et al., 2012). Other in vitro studies have demonstrated that
VWF protects FVIII from being endocytosed by human den-
dritic cells and subsequently being presented to FVIII-specific
T cells (Dasgupta et al., 2007; Kaveri et al., 2007).
However, numerous clinical studies and systematic reviews
have yielded conflicting results, with the majority of the
studies only including severe HA patients, and studies focus-
ing on nonsevere haemophilia are scarce (Wight & Paisley,
2003; Gouw et al., 2007, 2013, 2013; Iorio et al., 2010; Fran-
chini et al., 2012).
Recently studies in severe HA patients showed that sec-
ond-generation recombinant FVIII concentrates were associ-
ated with a higher risk for inhibitor development (Gouw
et al., 2013; Collins et al., 2014; Calvez et al., 2014).
In addition, in 2016 the SIPPET study was published, a
multicentre open label randomised study in nonsevere HA
patients, comparing plasma-derived and recombinant FVIII
concentrates. The results of the SIPPET study showed an
association between recombinant FVIII concentrates and the
risk of inhibitor development in severe HA patients.
These results have perpetuated the debate about the type of
FVIII concentrate being a risk factor for inhibitor develop-
ment. In the search for risk factors for inhibitor development,
nonsevere HA has been a neglected area of research. More-
over, studies have shown several differences and similarities
between severe and nonsevere patients with regard to inhibitor
development, e.g. in treatment, underlying biology and genet-
ics (Fijnvandraat et al., 2003; d’Oiron et al., 2008; Peerlinck &
Jacquemin, 2010; Castaman & Fijnvandraat, 2014).
In this nested case–control study we analysed the associa-
tion of the type of FVIII concentrate and inhibitor develop-
ment in nonsevere HA patients.
Methods
Patients
We conducted a case–control study, nested in a cohort of
2709 consecutive nonsevere HA patients (FVIII:C 2–40%),
who received at least one exposure to FVIII concentrate in 33
European centres and one Australian centre between 1 January
1980 and 1 January 2011. The institutional review boards of
all participating centres approved the study and have indicated
that signed informed consent was not required.
All patients from the source population were followed-up
from birth until death, emigration, loss to follow-up, or the
end of the study. For each centre, we individually decided if
data was available and reliable up until start of inclusion. For
further information, we refer to previously published papers
of the INSIGHT study, specifically the first paper published
on the case–control study. (Eckhardt et al., 2013; Eckhardt
et al., 2015; van Velzen et al., 2015; van Velzen et al., 2016,
2017, 2017).
Nonsevere HA patients who developed a clinically relevant
inhibitor during follow-up were identified as case patients.
One to four control patients (nonsevere HA patients without
inhibitor development at the time of data collection) were
matched by date of birth and cumulative number of expo-
sure days (CEDs) to FVIII concentrates to each case (van
Velzen et al.).
The cases and matched controls that received >75 CEDs
were excluded from this primary analysis. Unfortunately,
there were not enough patients, even in this large cohort,
with this number of CEDs. Due to the low numbers, the
uncertainty of the estimates would have been too large and
we thus had to restrict our analyses to the exposure period
in which we could produce reliable estimates, i.e. the period
before 75 CEDs.
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Data collection
Baseline clinical data were collected for the complete
INSIGHT cohort, including the FVIII:C baseline level, cumu-
lative number of EDs, F8 genotype, ethnicity, family history
of haemophilia A and inhibitor development. F8 genotype
was categorised into three categories (low risk mutation, high
risk mutation, unknown) based on the HAMSTERS and
CHAMP databases (Center for Disease Control & Prevention.
CHAMP: CDC Haemophilia A Mutantion Project. http://
www.cdc.gov/ncbddd/hemophilia/champs.html; Green et al.,
2008). We chose these two references because they are a bet-
ter random sample, compared to our own INSIGHT data-
base in which there is a stronger selection bias due to the
nature of the study and this specific determinant. If for a
mutation listed in the CHAMP F8 mutation list and/or in
the HAMSTERS database there was a reported history of
inhibitor development, this mutation was classified as high
risk mutation, and if there was no reported inhibitor devel-
opment, the mutation was classified as low risk mutation.
For the cases and controls, detailed clinical data of every
FVIII exposure day were collected until inhibitor develop-
ment in cases, and up to the same number of EDs in con-
trols, including the calendar date of every exposure day (of
each patient), type, dose and mode of administration of
FVIII product, mode and reason for treatment.
Outcome
The primary outcome was clinically relevant inhibitor devel-
opment, defined as having at least two consecutive positive
Bethesda inhibitor assay titres of ≥10 Bethesda Units (BU)
per ml. Patients with inhibitor titres between 06 and
10 BU/ml had to fulfil one of the following two criteria to
be classified as having a clinically relevant inhibitor: i) a
decrease in endogenous FVIII plasma level to at least 50% of
the baseline level, or ii) a reduced half-life of <6 h after FVIII
concentrate administration. Patients who were not tested for
inhibitors during the follow-up period and who had no clini-
cal features of inhibitor development (e.g. increased bleeding
tendency) were classified as negative for inhibitors.
Determinants
Factor VIII concentrates. For every exposure day of each
patient, we collected information on the type of FVIII con-
centrate administrated. Patients were classified into categories
representing the most frequently used type of FVIII concen-
trate. This was defined by the type of FVIII concentrate that
was used for at least 50% of the EDs. If the type of concen-
trate was unknown for more than 50% of the EDs in a
patient, we classified this patient into the category ‘un-
known’. This was also done for the first and the last 10 EDs
of every patient.
For the sensitivity analysis of recombinant FVIII concen-
trate compared to plasma-derived FVIII concentrate, we
defined the most frequently used type of FVIII concentrate
as the concentrate used for at least 80% of the EDs with one
type of concentrate. For the majority of the patients in our
cohort, mainly one type of concentrate was used.
Firstly, we grouped all plasma-derived FVIII concentrates
together and compared them to all recombinant FVIII concen-
trates grouped together. Secondly, we analysed whether the
amount of von Willebrand factor antigen present in a FVIII
product was associated with the risk of inhibitor development.
We compared FVIII products containing no von Willebrand
factor (all recombinant FVIII products), to products contain-
ing <001 International Units (IU) of von Willebrand factor
antigen per IU of FVIII antigen (‘low VWF’) and products
containing ≥001 IU of von Willebrand factor per IU of FVIII
antigen (‘high VWF’). This classification was based on the
classification used in the RODIN study (Gouw et al., 2013).
Thirdly, the different generations of recombinant FVIII
products (first-generation recFVIII, second-generation
recFVIII and third-generation recFVIII) were compared to all
plasma-derived products.
For all cases, the last FVIII infusion was defined as the last
one administered before inhibitor detection (the first positive
Bethesda inhibitor test), and for controls the last factor infu-
sion was the last CED that was included, based on the num-
ber of EDs of the matched case.
Dose. To study the dose as a determinant, we calculated the
mean dose FVIII concentrate in International Units (IU) per
kilogram bodyweight (IU/kg) of all EDs. In the majority of
the patients, only the total administered dose of FVIII concen-
trate was available for each ED. To calculate the dose in IU/
kg/ED we imputed the weight of the patients on that specific
ED using age-weight statistics (for adults) and growth curves
(for children). The mean dose of all EDs for each patient was
calculated and this was classified into 3 categories: 0–25 IU/
kg, 25–45 and >45 IU/kg per ED (van Velzen et al., 2017).
Peak treatment. We defined three categories of peak treat-
ment moments:
1. at least three consecutive EDs to FVIII concentrate within
a maximum of five calendar days,
2. at least five consecutive EDs within a maximum of 5–10
calendar days
3. at least 10 consecutive EDs within a maximum of 14 cal-
endar days.
To adjust for peak treatment moments in the analyses, we
classified all patients into the following categories:
4. patient has never had a peak treatment moment during
follow-up
5. patient has had at least one peak treatment moment with
three consecutive EDs during follow-up
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6. patient has had at least one peak treatment moment with
five consecutive EDs
7. patient has had at least one peak treatment moment with
10 consecutive Eds.
Surgery. We collected data on the reason for treatment on
every exposure day of each patient. To adjust for surgery, we
classified patients into the following categories:
8. did this patient ever had a surgical intervention during
follow-up? (yes/no)
9. did this patient have surgery in the last six months before
end of follow-up? (yes/no)
For further details on all the determinants described
above, please see Methods section in this paper on the
INSIGHT case–control study.
Missing data
The missing calendar dates of EDs were unconditionally
imputed with the middle value between the dates before and
after the missing dates (<05%).
If the reason for treatment was missing (55%) for EDs
one calendar day before or after an ED for which the reason
for treatment was known, the missing value was replaced
with the reason for treatment of that ED. In all other cases,
missing values were unconditionally imputed with ‘trauma’
as the reason for treatment, since the assumption was made
that this is the most probable reason for treatment in this
patient group when reason of treatment was missing.
In the majority of the patients, only the total administered
dose of FVIII concentrate was available for each ED. To cal-
culate the dose in IU/kg/ED, we imputed the weight of the
patients on that specific ED, using age-weight statistics (for
adults) and growth curves (for children) (Centraal Bureau
voor de Statistiek; Royal College of Paediatrics & Child
Health; Australasian Paediatric Endocrine Group; McDowell
et al., 2008; Australian Bureau of Statistics, 2012; Destatis
Statistisches Bundesamt, 2013; Food & Agriculture Organiza-
tion of the United Nations, 2015). The mean dose of all EDs
for each patient was calculated and this was classified into
three categories: 0–25 IU/kg, 25–45 and >45 IU/kg per ED.
Missing values of the FVIII dose (14%) were replaced with a
median dose calculated with all EDs with that specific treat-
ment indication in that specific treatment centre.
When the type of FVIII concentrate was missing (10%)
for an exposure day and this ED was one of several subse-
quent EDs for one specific reason for treatment, the missing
value was replaced with the type of FVIII concentrate that
was reported for the other EDs.
Data analyses
To analyse the association between the type of FVIII concen-
trate and inhibitor development, we used conditional logistic
regression methods. This method accounts for the matching
of cases and controls, and analysis is performed using the
matching groups (i.e. one case and 1–4 controls).
Crude as well as adjusted odds ratios (aORs) are pre-
sented. We adjusted for determinants that could have possi-
bly confounded the associations studied, independent of
their statistical significance in univariate analyses. The pre-
defined confounders we adjusted for in the analysis are:
endogenous FVIII level, ethnicity, F8 genotype, positive fam-
ily history for inhibitors, age at first ED and at last ED, cal-
endar date, reason for treatment at first exposure, surgery,
dose and peak treatment moment.
Results
Patient characteristics
In total, 7832 EDs for 298 patients were included in this
case–control study. Figure 1 shows an overview of the patient
inclusion.
The median age at first exposure was 23 years (interquar-
tile range (IQR) 5–44) and the median baseline (endoge-
nous) FVIII level was 8 IU/dL (IQR 4–14). The 75 cases
(inhibitor patients) developed an inhibitor after a median of
25 ED (IQR 12–40) and the median inhibitor peak titre was
7 BU/ml (IQR 2–26). Baseline characteristics for cases and
controls are shown in Table I (van Velzen et al.).
Plasma-derived versus recombinant factor VIII
In total, 179 patients were mainly treated with plasma-
derived FVIII concentrates, and in 39 of these patients an
inhibitor occurred during follow-up, compared to 36 patients
of the 119 patients mainly treated with recombinant FVIII
concentrates. All crude and adjusted relative risks for inhibi-
tor development are displayed in Table II.
The risk of inhibitor development after treatment with
recombinant FVIII products was not significantly increased
compared to treatment with plasma-derived products in this
study, whether analysed for all ED aOR 096, 95% confidence
interval (CI) 036–252) or the first 10 EDs (aOR 084, CI
031–231) or last 10 EDs (aOR 127, CI 051–319).
Plasma-derived FVIII concentrates: von Willebrand
factor-content
The majority of the patients (94, 53%) treated with plasma-
derived FVIII concentrates received plasma-derived concen-
trates with a high von Willebrand factor content.
Compared to FVIII products containing no von Wille-
brand factor, the risk for inhibitor development was similar
for FVIII products with a low von Willebrand content (aOR
169, CI 038–745) and for those with a high von Willebrand
content (aOR 111, CI 038–333). This did not substantially
change when the von Willebrand content of the type of
A. S. van Velzen et al.
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concentrate used mainly for the first and last 10 EDs was
analysed.
Recombinant FVIII concentrates: first, second and third
generation concentrates
There was no difference in the risk for inhibitor development
when comparing first-generation recombinant FVIII concen-
trates, second-generation concentrates and third-generation
concentrates to plasma-derived FVIII concentrates, as shown
in Table IIC.
Sensitivity analyses
The result of the sensitivity analysis (please see Methods section)
regarding the use of plasma-derived FVIII versus recombinant
FVIII was comparable to the primary analysis (unadjusted OR
184, CI 094–362 and aOR 119, CI 042–336).
Discussion
In this nested case–control study we investigated the associa-
tion of the type of FVIII concentrate with inhibitor develop-
ment among 295 nonsevere HA patients. We did not find an
increased risk for inhibitor development for any type of
FVIII concentrate – either when comparing recombinant
FVIII concentrates to plasma-derived FVIII concentrates, or
for specific types of FVIII concentrates.
However, the results of the recently published SIPPET
study in severe HA showed different results. This was a
multicentre open label randomised study, including 251
patients with a median follow-up of 22 EDs. After adjust-
ment for confounders, recFVIII was associated with a 70–
90% higher incidence on inhibitor development in severe
HA patients (Peyvandi et al., 2016). In comparing the dif-
ferent types of recFVIII to pdFVIII concentrates, several
studies have found an increased risk for second generation
Eligible pa ents
n = 2709
Selected as controls
n = 291
Non-inhibitor pa ents
n = 2602
Inhibitor pa ents
n = 107
Included as cases
n = 75
Excluded pa ents n = 32
19 in >75 ED group
9 pa ents exact number ED unclear
4 pa ents from 2 centers that did not
par cipate in case-control study
Included as controls
n = 223
Excluded pa ents n = 68
51 in >75 ED group
7 pts not sufficient EDs entered in DB
10 pts exact number ED unclear
Fig 1. Inclusion of patients for case–control
study from INSIGHT cohort.
Table I. Baseline characteristics.
Characteristics
All patients (n = 298) Cases (n = 75) Controls (n = 223)
Median (IQR) Median (IQR) Median (IQR)
Number (%) Number (%) Number (%)
Baseline FVIII level, IU/l 8 (4–14) 9 (5–14) 8 (4–14)
Age at first ED, years 23 (5–44) 26 (6–51) 21 (5–42)
Age at last ED, years 30 (13–54) 37 (14–61) 29 (13–52)
Number of ED’s 20 (10–37) 25 (12–40) 18 (9–36)
Caucasian ethnicity 285 (96) 71 (95) 214 (96)
Family history of inhibitors
Yes 13 (44) 8 (11) 5 (2)
No 195 (654) 43 (57) 152 (68)
Unknown 90 (302) 24 (32) 60 (30)
F8 genotype
High risk mutation 93 (31) 41 (55) 52 (23)
Low risk mutation 91 (31) 12 (16) 79 (35)
Unknown 114 (38) 22 (29) 92 (41)
Values are medians (interquartile ranges).
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recFVIII concentrate (Gouw et al., 2013; Calvez et al., 2014;
Collins et al., 2014).
The difference between these results in severe HA and
our findings might be caused by the differences in study
design (the SIPPET study was a randomised trial) but also
by differences in immunological and treatment characteris-
tics between severe and nonsevere HA. Firstly, severe HA
patients have no measurable FVIII activity, which in many
Table II. Type of concentrate and inhibitor development.
A) All plasma-derived versus all recombinant concentrates
Characteristics No. pts Crude OR (95% CI) Number of events Adjusted OR (95% CI)*
Type of FVIII concentrate
All EDs
Plasma -derived (ref.) 179 1 39 1
Recombinant 119 170 (091–318) 36 096 (036–252)
First 10 EDs
Plasma -derived (ref.) 190 1 42 1
Recombinant 108 178 (089–347) 33 084 (031–231)
Last 10 EDs
Plasma -derived (ref.) 128 1 37 1
Recombinant 170 164 (087–309) 38 127 (051–319)
B) Plasma-derived FVIII concentrates; different von Willebrand factor (VWF) content
Characteristics No. pts Crude OR (95% CI) P-value Adjusted OR (95% CI)* P-value
All EDs
No VWF 119 1 1
Low VWF 42 077 (032–184) 056 169 (038–745) 049
High VWF 94 056 (026–122) 015 112 (037–333) 084
Other/Unknown 43 043 (016–118) 011 060 (015–250) 049
First 10 EDs
No VWF 108 1 1
Low VWF 37 043 (015–122) 060 (012–298)
High VWF 106 062 (028–137) 130 (043–393)
Other/Unknown 47 061 (025–151) 188 (045–774)
Last 10 EDs
No VWF 128 1 1
Low VWF 42 071 (029–169) 052 (012–225)
High VWF 89 066 (031–145) 108 (036–324)
Other/Unknown 39 036 (012–111) 061 (014–276)
C) Recombinant FVIII concentrates; first, second and third generation
Characteristics No. pts Crude OR (95% CI) Adjusted OR (95% CI)*
All EDs
Plasma-derived 179 1 1
Generation recombinant FVIII concentrate
First generation 52 138 (062–311) 091 (028–298)
Second generation 45 240 (110–527) 105 (028–384)
Third generation 7 072 (009–751) 017 (001–287)
Other/Unknown 15 118 (030–467) 142 (019–1037)
First 10 EDs
Plasma-derived 190 1 1
First generation 54 153 (067–352) 074 (023–239)
Second generation 31 274 (109–687) 160 (039–644)
Third generation 4 158 (015–1644) 044 (002–1335)
Other/Unknown 19 098 (028–339) 019 (002–156)
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is caused by an absence of extracellular FVIII protein. How-
ever, nonsevere patients produce endogenous FVIII that
often differs only by a single amino-acid from the wild type
(infused) FVIII protein. This may result in a different
immunological response in severe HA patients compared to
nonsevere. Secondly, the standard treatment for severe HA
patients is prophylactic treatment, starting at a young age,
and due to the prophylactic regimen these patients receive
the first 15–20 EDs in a rather brief time period. Most
nonsevere HA patients do not need prophylactic treatment
and only receive FVIII to control bleeding after trauma or
surgery. Therefore, nonsevere HA patients mostly receive
their first treatment at a later age and the administration of
FVIII concentrates is almost always on demand with the
appearance of some amount of tissue damage. The com-
bined action of risk factors may contribute to different
results of risk factor analysis in inhibitor development in
nonsevere HA. Also, the older age of first exposure may
suggest that our population phenotype was a phenotype
with lower bleeding, and this may have contributed to the
lack of finding a difference.
Until now it has not been clarified which phase in treatment
is the most important with regard to inhibitor development.
The first exposures with FVIII concentrate could be the most
important, when the immune system of a patient processes the
FVIII concentrate for the first time. On the other hand, the last
exposures to FVIII, promptly before inhibitor development,
could be the moment the immune system becomes disrupted.
Therefore, we analysed the first and last period of treatment
(first and last 10 EDs), but we did not find a difference in inhi-
bitor risk for one type of concentrate there either.
One of the unique strengths of this study is the case–con-
trol study design and the way patients were matched for the
CEDs. We were able to include a large number of patients
and collect detailed data on every ED for all these patients.
Due to the detailed data collection, we were able to adjust
for all putative confounders.
Thirdly, the duration of the observation period of the
study was extensive; we were therefore able to include suffi-
cient patients that were treated with plasma-derived FVIII
concentrates. Recent studies often include a small number of
patients treated with plasma-derived FVIII concentrates due
to a shorter observation period. This causes an uneven distri-
bution of patients over the different product groups.
In our study, there is heterogeneity of FVIII concentrates
and of each class of FVIII concentrates, because we collected
data from multiple centres in order to be able to study this
rare disease. There is a great number of patients who were
treated with several different products, and we have therefore
chosen the most frequently used and the last product used,
as shown in Table IIA–C.
Even though this is a large study for this specific patient
group, the number of patients in some of the groups for dif-
ferent types of concentrates was still small. Therefore, our
analysis for the subtypes of FVIII concentrates may be under-
powered, increasing the chance of a type II error (the analy-
sis not showing a difference in risk for inhibitor
development is a false negative finding).
Due to the long observation period and the retrospective
character of this study, there was missing data in different
variables. Due to the missing data, there was a need for data
imputation which may have influenced the outcome of our
analyses.
Recently, several studies on the type of FVIII concentrate
and the risk for inhibitor development in severe HA have
been published, all showing an increased risk for second-gen-
eration recombinant FVIII concentrates (Gouw et al., 2013;
Calvez et al., 2014; Collins et al., 2014). The univariate analy-
sis in our study did show an increased risk for inhibitor
development for second-generation FVIII concentrates, but
after adjustment for confounders, this finding did not reach
statistical significance. Again, this may be caused by the fact
that the total number of patients treated with a second-gen-
eration FVIII concentrate is small.
To conclude, in this nested case–control study including
nonsevere HA patients, the type of FVIII concentrate was not
associated with the development of inhibitors. These findings
suggest that inhibitor development in nonsevere HA patients
may be dependent on different determinants than inhibitor
development in severe HA patients.
Table II. (Continued)
C) Recombinant FVIII concentrates; first, second and third generation
Characteristics No. pts Crude OR (95% CI) Adjusted OR (95% CI)*
Last 10 EDs
Plasma-derived 171 1 1
First generation 49 117 (051–273) 079 (024–264)
Second generation 54 229 (103–513) 187 (055–642)
Third generation 11 086 (016–477) 014 (001–236)
Other/Unknown 13 121 (030–487) 100 (007–1412)
Table A, B and C: Values are medians (interquartile ranges); Number of patients in each group based on cut-off of >50% of type of concentrate.
*Adjusted for confounders: endogenous FVIII level, ethnicity, F8 genotype, positive family history for inhibitors, age at first ED and at last ED,
calendar date, reason for treatment at first exposure, surgery, dose, peak treatment.
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